Trial Profile

A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER, SINGLE-DOSE STUDY TO EVALUATE THE BIOEQUIVALENCE OF CANDIDATE CAPSULE FORMULATIONS OF PF-06651600 TO TABLETS AND ESTIMATE THE EFFECT OF HIGH-FAT MEAL ON BIOAVAILABILITY IN HEALTHY PARTICIPANTS

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ritlecitinib (Primary) ; Ritlecitinib (Primary)
Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
Focus Pharmacokinetics
Sponsors Pfizer

02 Aug 2021 Status changed from recruiting to completed.
09 Jun 2021 Planned End Date changed from 17 Jul 2021 to 25 Jul 2021.
09 Jun 2021 Planned primary completion date changed from 17 Jul 2021 to 25 Jul 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com